Plantar Fasciitis Treatment: Influence of the Possible Presence of Subchondral Bone Edema (THEAL-F)

Standard treatments of plantar fasciitis include stretching exercises of the posterior muscle chain and plantar fascia, taking anti-inflammatories, cortisone infiltration or biostimulation with physical therapies (low energy laser therapy, shock waves, ultrasound therapy, etc.). In non-responsive forms to conservative treatments, surgical treatment can be undertaken.

Laser therapy is indicated for plantar fasciitis, in particular for its biological anti-inflammatory, anti-edema and reparative effects on the plantar fascia; to date, the potential effects also on the underlying bone edema component, when present, which aggravates and self-maintains the ongoing pathology are not known.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Plantar fasciitis is one of the most common causes of heel pain; the pain is more intense in the morning, tends to decrease during the day with movement, to flare up after sitting for a long time. It presents itself as inflammation and contextual degeneration of the insertion of the fascia that covers the muscles present at the level of the sole of the foot, with progressive evolution and possible calcification of the insertion. The incidence is between 9 and 20% of the population, with a higher incidence in middle-aged obese women and in young male runners. The diagnosis makes use of radiography, to verify any local deformities or the presence of the subcalcaneal spur, and ultrasound, to investigate the integrity of the fascia and its thickening. MRI images are useful for better studying the heel bone and plantar fascia, especially for discerning other various causes of heel pain, including stress fractures, tarsal tunnel syndrome, and Achilles tendinopathy. Signal changes with bone edema are sometimes found in association with plantar fasciitis and may be indicative of or represent the result of avulsive trauma, stress, intraspongious fractures or a combination of these situations. These MRI images are similar to those described in the elbow in some patients with epicondylitis, where overuse can cause increased bone edema on T2-weights. Previous studies have shown the presence of bone edema at the level of the heel on MRI in 35% of patients with plantar fasciitis. Plantar fascia evaluation with a dedicated magnetic resonance scanner in weight-bearing position: our experience in patients with plantar fasciitis and in healthy volunteers. Maier et al demonstrated that the presence of calcaneal bone edema is a highly predictive factor for improved response to shock wave treatment. Often the finding of a thickening of the fascia and the signal changes of the soft tissues do not correlate with the clinical response, while the presence of bone edema is highly predictive (positive predictive value 0.94, sensitivity 0.89, specificity 0.8).

Study Type

Interventional

Enrollment (Actual)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bari, Italy, 70124
        • Angela Notarnicola

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. history of heel pain for at least 3 months prior to enrollment,
  2. Pain on palpation of the medial calcaneal tubercle or proximal plantar fascia,
  3. plantar fascia thickness of 4.0 mm or greater.

Exclusion Criteria:

  1. age below 18 years of age
  2. history of systemic disease
  3. pregnancy
  4. Previous surgery on the lower limbs
  5. diagnosis of fibromyalgia, neurological disease, Achilles tendinopathy, metatarsalgia, acute ankle sprain, tarsal tunnel syndrome, or heel joint syndrome
  6. body mass index (BMI) greater than 35 kg/m2
  7. wounds, infections in the treatment area
  8. altered sensation in the treatment area
  9. skin pigmentation alterations in the area to be treated (tattoo, dyschromia)
  10. metal implants in the treatment area
  11. History of oral or injected corticosteroid therapy within the past six weeks
  12. Diagnosis of neurological heel pain (radiculopathy)
  13. diagnosis of systemic inflammatory arthritis (rheumatoid arthritis, etc.)
  14. other acute pathologies (febrile fever, cold, etc.) requiring treatment
  15. other painful conditions requiring painkillers (toothache, back pain, etc.)
  16. neoplasms
  17. cardiac pacemaker or other device.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control group

Patients will perform four daily stretching exercises (three sets of 30 seconds), for 6 weeks.

  1. Hamstring and ankle plantar flexor stretch (straight leg raise in supine position)
  2. self-stretching of the surae muscles: the patient bends forward in a standing position with the affected foot farthest from the wall, keeping the heel on the floor; 3. the soleus muscle is exercised with the knee flexed and the gastrocnemius muscle with the knee extended

4. Plantar fascia self-stretch: In a seated position, the patient crosses the affected foot over the contralateral thigh and passively extends the metatarsophalangeal joints .

In the first session, the volunteers will be trained on how to perform the exercises correctly and will be monitored once a week.

Experimental: experimental group

The protocol provides for the administration of 10 polymodal high energy laser therapy sessions, to be carried out every other day. The THEAL device (Mectronic, Bergamo) allows to deliver 4 wavelengths (650 nm, 810 nm, 980 nm and 1064 nm), with continuous and pulsed mode, with power up to 20 W.

Patients will perform stretching exercise like those of the control group.

laser therapy high intensity
Other Names:
  • laser

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
recovery of pain
Time Frame: change between baseline to 2 months
The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between "no pain" and "worst pain."
change between baseline to 2 months
recovery of pain
Time Frame: change between baseline to 6 months
The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between "no pain" and "worst pain."
change between baseline to 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
functional recovery
Time Frame: change between baseline to 2 months
The Foot Function Index (FFI) measures the effect of foot problems on function in terms of pain and disability.The scores range from 0 to 100; the higher the score, the more limitation/pain/disability is present. The scores range from 0 to 100; the higher the score, the more limitation/pain/disability is present.
change between baseline to 2 months
functional recovery
Time Frame: change between baseline to 6 months
The Foot Function Index (FFI) measures the effect of foot problems on function in terms of pain and disability.The scores range from 0 to 100; the higher the score, the more limitation/pain/disability is present. The scores range from 0 to 100; the higher the score, the more limitation/pain/disability is present.
change between baseline to 6 months
perception of clinical improvement
Time Frame: change between baseline to 2 months
Maudsley and Roles scale scores range from 0-4 points for excellent to poor
change between baseline to 2 months
perception of clinical improvement
Time Frame: change between baseline to 6 months
Maudsley and Roles scale scores range from 0-4 points for excellent to poor
change between baseline to 6 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
band thickness
Time Frame: change between baseline to 2 months
ultrasound image to measure of fascia thickness, measured in mm
change between baseline to 2 months
band thickness
Time Frame: change between baseline to 6 months
ultrasound image to measure of fascia thickness, measured in mm
change between baseline to 6 months
presence of edema
Time Frame: change between baseline to 2 months
MRI image to verify the presence or absence of bone edema (dichotomous answer)
change between baseline to 2 months
presence of edema
Time Frame: change between baseline to 6 months
MRI image to verify the presence of absence or bone edema (dichotomous answer)
change between baseline to 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2023

Primary Completion (Actual)

January 1, 2025

Study Completion (Actual)

May 1, 2025

Study Registration Dates

First Submitted

June 13, 2023

First Submitted That Met QC Criteria

June 22, 2023

First Posted (Actual)

June 29, 2023

Study Record Updates

Last Update Posted (Actual)

May 25, 2025

Last Update Submitted That Met QC Criteria

May 23, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • THEAL-fasc

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fasciitis, Plantar

Clinical Trials on THEAL (Mectronic, Bergamo)

Subscribe